戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ogramme, both thought to be unrelated to the investigational drug.
2 r basis for the binding and function of this investigational drug.
3 reatment with a GlyT1 inhibitor or any other investigational drug.
4 ntral fat accumulation were recorded for the investigational drug.
5  used to inform the risks and benefits of an investigational drug.
6 act as suitable carriers for the delivery of investigational drugs.
7 o as to improve the efficacy of approved and investigational drugs.
8 creasing prevalence of allosteric ligands as investigational drugs.
9  cell invasive potential form a new class of investigational drugs.
10 ure axis was associated with response to 105 investigational drugs.
11 pproved drugs, 6242 marketed drugs, and 9684 investigational drugs.
12 ally on their interactions with clinical and investigational drugs.
13 n treatment effect estimation for any of the investigational drugs.
14 ng clinical adverse drug reactions (ADRs) of investigational drugs.
15 role, and the Right to Try pathway to access investigational drugs.
16 nt to available therapies, which can include investigational drugs.
17 py, immunotherapy, radium-223 ((223)Ra), and investigational drugs.
18 , mechanistically validated using additional investigational drugs.
19 ased methods in doping control to detect new investigational drugs.
20 s of small molecules, including approved and investigational drugs.
21                                          The investigational drug 4d more effectively inhibited the m
22 macogenomics datasets profiling approved and investigational drugs across cell lines from diverse tis
23 s new "breakthrough therapy" designation for investigational drugs adds to the agency's portfolio of
24 d and Drug Administration (FDA)-approved and investigational drugs against hundreds of targets, defin
25                                              Investigational drugs aim to reduce HTT levels by repres
26                                          The investigational drug and placebo were identical in their
27 work-based screens of >2,900 FDA-approved or investigational drugs and identify 23 with significant n
28 019, evaluating the characteristics of these investigational drugs and the outcomes of these drug dev
29 d compare the various therapeutic platforms, investigational drugs, and clinical trials targeting geo
30 l of these proteins have been the targets of investigational drugs, and epidermal growth factor recep
31  leading drug candidates, several designated investigational drugs, and some medical devices, as well
32 ng to abandonment of potentially efficacious investigational drugs, and unexpected deadly adverse eve
33                               Currently only investigational drugs are available in case of radiologi
34 his challenge by testing 128 FDA-approved or investigational drugs as either single agents or in 768
35  research on adherence to placebo-controlled investigational drug by way of drug detection in active-
36  the formation of these byproducts, with the investigational drug C20D(3)-vitamin A, results in faste
37 ne-3-carboxamide (VX-770, 48, ivacaftor), an investigational drug candidate approved by the FDA for t
38 asma concentration-time results of NVP-1, an investigational drug candidate, observed in the plasma s
39 F-FDG PET for guiding the selection of novel investigational drugs, choosing dose in early-phase clin
40  efficacy of a synthetic form of psilocybin (investigational drug COMP360) adjunct to a selective ser
41                                          The investigational drug DNL343 was advanced into Phase 1 an
42 translate into differential responses to the investigational drug EH301.
43                                    UM171, an investigational drug for haematopoietic stem cell transp
44                               Eritoran is an investigational drug for sepsis treatment that resembles
45     The nucleotide analogue remdesivir is an investigational drug for the treatment of human coronavi
46  with powerful antioxidant properties, is an investigational drug for uterine fibroids.
47  Twenty proteins are targeted by approved or investigational drugs for asthma or other conditions, su
48 atory scrutiny that affects manufacturers of investigational drugs for early-phase clinical trials en
49  are targeted by a number of widely used and investigational drugs for the treatment of epilepsy, arr
50 iscovery, repurposing clinically approved or investigational drugs for the treatment of tuberculosis
51 cipating oncologists felt confident pursuing investigational drugs for treatment use, despite the abs
52 compounds, including clinically approved and investigational drugs, for their cytotoxicity in the pre
53 .3-angstrom resolution and the other with an investigational drug, GLPG1837, at 3.2-angstrom resoluti
54 .3-angstrom resolution and the other with an investigational drug, GLPG1837, at 3.2-angstrom resoluti
55 new drug is time consuming, many approved or investigational drugs have been repurposed for COVID-19
56       For the past several years a number of investigational drugs have demonstrated activity in pati
57 otegrast (PLN-74809) is an oral, once-daily, investigational drug in development for the treatment of
58 to rapid growth of the field, with dozens of investigational drugs in active clinical trials.
59                The screening of approved and investigational drugs in cell-based phenotypic assays ca
60 ccurately predict the safety and efficacy of investigational drugs in humans.
61 ere are newly approved treatments as well as investigational drugs in the pipeline, including the new
62 increases greater than those seen with other investigational drugs in this class and LDL-C lowering e
63 -class styrylbenzene based antibiotic, is an investigational drug indicated for Clostridium difficile
64                    The mechanistically novel investigational drug ITI-007 was effective for the treat
65                                          The investigational drug lenacapavir accesses unoccupied hyd
66 ating agents (HMAs), lenalidomide (LEN), and investigational drugs, may be used after ESA failure in
67             Symptom reduction was 40.7% with investigational drugs (n = 4,510), 41.7% with active com
68                                          The investigational drug, nivolumab, was administered intrav
69 ifies an apoptotic biomarker (PYCARD) for an investigational drug obatoclax.
70 at have received long-term treatment with an investigational drug or device.
71  are randomized to standard therapy plus the investigational drug or standard therapy plus placebo ar
72 his method is constrained by the need for an investigational drug permit.
73                                     For both investigational drugs, PET responses tended to be greate
74 d in a 3:1:1 ratio to receive fixed doses of investigational drug, placebo, or haloperidol for 6 week
75                  No adverse reactions to the investigational drug product and no abnormal clonal prol
76  and reduce costs for developing and testing investigational drugs reducing number of laboratory anim
77           Since the introduction of this new investigational drug, scintigraphic imaging has been per
78 noids as a relevant preclinical platform for investigational drug screening.
79 ngs show that transient exposure to this new investigational drug should be useful for controlling p5
80 reveals potential drug targets, with several investigational drugs showing efficacy in vitro.
81  Task Force of the National Cancer Institute Investigational Drug Steering Committee convened an inte
82 ly reproducible and allows for evaluation of investigational drugs targeting IL-6-dependent MM cells
83                    AML patients treated with investigational drugs targeting mutant FLT3, including Q
84 ibutes and limitations of recently disclosed investigational drugs targeting Na(V)1.7 and review evid
85  biology of WM and allows the study of novel investigational drugs targeting WM cells in the huBM mil
86 t the proteomic level and compared them with investigational drug targets.
87 ung colonization could be abrogated using an investigational drug that attenuates Stat3 activity, imp
88 rolone is a first-in-class anti-inflammatory investigational drug that has shown evidence of efficacy
89 atitis C immunoglobulin (HCIG) Civacir is an investigational drug that is currently being developed i
90 an hepatitis C immune globulin Civacir is an investigational drug that is currently being developed i
91 ted to participate in a clinical trial of an investigational drug that is now widely used to treat br
92                                  BT-11 is an investigational drug that reduces inflammation in the gu
93 r (VEGF) therapy and ionizing radiation, and investigational drugs that address different targets alo
94 ents, has led to the clinical development of investigational drugs that restore function to defective
95                 For 28 clinical drugs and 22 investigational drugs, the model identified 58 unknown d
96 reatment of systemic mastocytosis, including investigational drug therapy.
97 nd some of the limitations of this important investigational drug, these findings clearly demonstrate
98                Therefore, DNL343 is a useful investigational drug to explore the effects of ISR inhib
99 elerated approval pathway allows approval of investigational drugs treating unmet medical needs based
100 brain tumors referred to our institution for investigational drug trials.
101            It was demonstrated that, for the investigational drug under study, the matrix effect was
102 ho were lactating; or if they planned to use investigational drugs, vaccines, blood products, or any
103 ity defect can be partially corrected by the investigational drug VX-809 (3-[6-[[[1-(2,2-difluoro-1,3
104 at several of these compounds, including the investigational drug VX-809, caused a much greater incre
105 ue and displayed an additive effect with the investigational drug VX-809.
106                                         This investigational drug was compared with the common antihy
107                                          All investigational drugs were well tolerated.
108 vity remains elusive for currently available investigational drugs, while their additional value in s
109 the basis of these data, multiarm studies of investigational drugs will require 25 evaluable subjects
110 lines require that potential interactions of investigational drugs with P-gp be explored, often this

 
Page Top